Predictive Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
AGPU$7.50+11.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | $8,728,660 | $22,071,523 |
| Accounts receivable | 333,697 | 331,196 |
| Inventories | 494,374 | 430,493 |
| Prepaid expense and other assets | 521,700 | 526,801 |
| Total current assets | 10,078,431 | 23,360,013 |
| Property and equipment, net | 1,233,910 | 1,833,255 |
| Intangibles, net | 252,457 | 253,865 |
| Lease right-of-use assets | 2,728,355 | 211,893 |
| Other long-term assets | 124,096 | 75,618 |
| Total assets | $14,417,249 | $25,734,644 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,342,027 | $943,452 |
| Note payable | 150,408 | - |
| Accrued expenses and other liabilities | 1,631,702 | 2,229,075 |
| Derivative liability | 1,376 | 13,833 |
| Contract liabilities | 308,091 | 602,073 |
| Lease liability | 517,427 | 94,237 |
| Total current liabilities | 3,951,031 | 3,882,670 |
| Other long-term liabilities | 5,459 | - |
| Lease liability – net of current portion | 2,188,979 | 86,082 |
| Total liabilities | 6,145,469 | 3,968,752 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, 20,000,000 shares authorized inclusive of designated below | ||
| Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of December 31, 2023, and December 31, 2022 | 792 | 792 |
| Common stock, $.01 par value, 200,000,000 shares authorized, 4,062,853 and 3,938,160 shares outstanding as of December 31, 2023, and December 31, 2022, respectively | 40,629 | 39,382 |
| Additional paid-in capital | 175,992,242 | 175,503,634 |
| Accumulated deficit | (167,761,883) | (153,777,916) |
| Total stockholders’ equity | 8,271,780 | 21,765,892 |
| Total liabilities and stockholders’ equity | $14,417,249 | $25,734,644 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.